This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager.
Dismiss

China opposes EU move to block funding for projects using Chinese inverters

( May 8, 2026, 03:00 GMT | Official Statement) -- MLex Summary: China said it opposes the EU’s plan to block funding support for projects using Chinese inverters, saying the bloc had labeled China a “high-risk country” without evidence and subjected Chinese products to unfair and discriminatory treatment. In a statement issued Thursday, China’s Ministry of Commerce said the move would undermine mutual trust between China and the EU, disrupt bilateral trade and supply-chain stability, and risk “decoupling.” It also warned that excluding Chinese products would hurt the EU’s green-transition goals and energy security. China urged the EU to stop what it called the stigmatization of China and to remove discriminatory measures against Chinese products, adding that Beijing would closely assess the impact on Chinese companies and take steps to protect their legitimate interests.Statement follows (in Chinese). ...

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login